4월 22일 10:20

Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating 75% Complete Response Rate at 3 Months with (nadofaragene firadenovec) in BCG-unresponsive NMIBC Patients1

Ferring Pharmaceuticals presented the first results from an ongoing Phase 3 trial in Japan assessing the efficacy and safety of nadofaragene firadenovec in patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bla...

4월 9일 15:28

Ferring achieved record sales driven by Reproductive Medicine combined with the emergence of Adstiladrin

Ferring achieved total revenues of €2.3 billion in 2024, an increase of 7% over the previous year at actual exchange rates (AER) and 8% at constant exchange rates (CER). This above market growth reflected the continued strong performance in Reprod...

2024년 10월 4일 16:50

Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility

Ferring Pharmaceuticals today announced the opening of a state-of-the-art global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin® (nadofaragene firadenovec-vncg). This represents a s...

2024년 10월 2일 09:42

Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study

Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC) in patients with mild-to-moderate ulcerative c...

2024년 4월 9일 14:28

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring

Ferring today published its 2023 Annual Report showing the company’s annual revenues were €2.2 billion, a decrease of -4% on the previous year at actual exchange rates (AER), but an increase of +1% at constant exchange rates (CER). EBITDA increase...

2023년 12월 11일 16:00

Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement

Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. The deal prov...

2023년 8월 24일 15:45

Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)

Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring’s Adstiladrin® (nadofaragene firadenovec-vncg) for up to US $500 million comprised of an ...

2023년 6월 22일 14:25

Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors

Ferring Pharmaceuticals announced today that Jean-Frédéric Paulsen has been appointed Executive Chairman of the Ferring Group, as it enters a new phase of growth following the approval of two innovative medicines by the US Food and Drug Administra...

2023년 6월 16일 14:16

Ferring Pharmaceuticals successfully increases its second Swiss Franc Bond offering by CHF 80 million

Ad hoc announcement pursuant to Art. 53 LR Ferring Pharmaceuticals announced the successful increase of its second Swiss Franc Bond offering by CHF 80 million. This senior unsecured bond transaction is issued by Ferring Holding SA with 8-year matu...

2023년 5월 10일 10:15

Four Analyses of Data for REBYOTA™ (fecal microbiota, live - jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023

Ferring Pharmaceuticals today announced three oral presentations and one poster presentation at Digestive Disease Week® (DDW 2023) for REBYOTA™ (fecal microbiota, live - jslm) a first-in-class single-dose microbiome-based treatment approved by the...

2023년 5월 10일 10:15

최초로 FDA가 승인한 재발성 클로스트리듐 디피실 감염 예방 위한 마이크로비옴 기반 치료제 레비오타의 데이터 분석 4가지, 2023년 DDW서 발표

페링 제약회사는 오늘 Digestive Disease Week®(DDW 2023)에서 레비오타(REBYOTA™: 분변 생미생물총 - jslm)에 대한 3건의 구두 발표와 1건의 포스터 발표가 있음을 알렸으며, 이 약은 18세 이상의 개인에서 CD(C. diff)에 대한 항생제 치료를 받은 후 재발성 CD 감...

2023년 4월 18일 17:07

Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health

Ferring Pharmaceuticals and BioInnovation announce a new strategic collaboration to accelerate innovation in women’s health. BioInnovation Institute Foundation (BII) and Ferring Pharmaceuticals A/S (Ferring) have expanded their collaboration with ...

2023년 3월 15일 14:40

Ferring Announces Abstract of the First Prospective, Multi-National, Real-world Study of Rekovelle® (follitropin delta) at the Congress of the Pacific Society for Reproductive Medicine

Today, an oral poster of the first post-authorisation Phase 4 real-world study, PROFILE, is being presented at the 13th Congress of the Pacific Society for Reproductive Medicine (PSRM) 2023 in Australia. The large, prospective, multi-national stud...

2023년 3월 15일 14:40

페링, 태평양 생식의학 협회 회의에서 Rekovelle®에 대한 최초의 전향적·다국적·실제 연구 초록 발표

오늘 최초의 허가 후 4상 실제 연구인 프로파일(PROFILE)의 오럴 포스터가 호주에서 열린 제13회 태평양 생식 의학 협회(Pacific Society for Reproductive Medicine, PSRM) 2023년 회의에서 발표되었다. 이 대규모의 전향적, 다국적 연구는 3상 RCT와 유사한 지속적...

2022년 12월 2일 09:20

Ferring Receives U.S. FDA Approval for REBYOTA® (fecal microbiota, live-jslm) - A Novel First-in-Class Microbiota-Based Live Biotherapeutic

Ferring Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approved REBYOTA® (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostrid...

2022년 12월 2일 09:20

페링, 레비요타(REBYOTA®) 미국 FDA 승인 획득… 업계 최초의 미생물군 기반 생균 치료제

페링제약(Ferring Pharmaceuticals)이 미국 식품의약국(FDA)이 레비요타(REBYOTA®, 대변 미생물군, live-jslm)를 승인했다고 발표했다. 레비요타는 업계 최초의 새로운 미생물군 기반 생균 치료제로 재발성 CDI에 대한 항생제 치료 후 18세 이상 성인의 C. 디피실리(...

2022년 10월 25일 16:55

Ferring Presents Seven New Analyses at ACG 2022 for RBX2660, Its Investigational Microbiota-Based Live Biotherapeutic

Ferring Pharmaceuticals today announced the presentation at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting of seven analyses for RBX2660, an investigational microbiota-based live biotherapeutic studied for its potent...

2022년 10월 25일 16:55

페링, ACG 2022서 연구용 미생물군 기반 생물 치료제 RBX2660 관련 7가지 새로운 분석 발표

페링제약(Ferring Pharmaceuticals)이 2022 미국소화기학회(ACG) 연례 과학 회의에서 연구용 미생물군 기반 생물 치료제인 RBX2660이 항생제 치료 후 재발성 C. 디피실리(CDI) 감염을 줄일 잠재력에 대한 7가지 분석 결과를 발표했다. PUNCH CD 오픈 라벨 2상 시험에...

2022년 10월 21일 11:00

Ferring Presents New Subgroup Analyses of Health-Related Quality of Life and Safety and Efficacy Data at IDWeek 2022 for RBX2660, Its Investigational Microbiota-based Live Biotherapeutic

Ferring Pharmaceuticals today announced the presentation of two subgroup analyses at Infectious Disease Week (IDWeek) 2022 that further characterize RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to redu...

2022년 10월 21일 11:00

페링, IDWeek 2022서 연구용 미생물군 기반 생물 치료제 RBX2660의 HRQL·안전성·효능 데이터 평가한 새로운 하위 그룹 분석 발표

페링제약(Ferring Pharmaceuticals)이 2022년 감염병 주간(IDWeek)에서 2개의 하위 그룹 분석 관련 프레젠테이션을 진행했다. 이번 프레젠테이션에는 항생제 치료 후 C. 디피실리 감염(CDI)의 재발을 줄이기 위해 연구 중인 미생물군 기반 생물학제제인 RBX2660에 대...

2022년 9월 23일 13:30

Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) issued a positive vote for RBX2660, an investigational microbiota-based live bioth...

2022년 9월 23일 13:30

페링, RBX2660 관련 미 FDA VRBPAC의 긍정적 표결 확보

미국 식품의약국(FDA)의 백신생물의약품자문위원회(VRBPAC)가 RBX2660의 효능·안정성 데이터를 표결에 부친 끝에 긍정적인 결과를 도출했다고 페링제약(Ferring Pharmaceuticals)이 22일 발표했다. RBX2660은 항생제 치료 후 ‘C. 디피실리 감염(C. difficile infecti...

2022년 8월 10일 11:10

Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) will hold a meeting on September 22, 2022, to review data supporting the biologics...

2022년 8월 10일 11:10

페링, 연구용 미생물군 기반 생물학제제 RBX2660 관련 미 FDA 자문위 회의 개최

페링제약(Ferring Pharmaceuticals)은 미국 식품의약처(FDA)의 백신 및 관련 생물학제제 자문위원회(VRBPAC)가 9월 22일 회의를 열어 RBX2660에 대한 생물학제제 허가 신청(BLA)을 입증하는 데이터를 검토할 예정이라고 9일 발표했다. RBX2660은 항생제 치료 후 C. ...

2022년 6월 10일 10:30

Ferring Announces New Collaboration for Development of Olamkicept

Ferring Pharmaceuticals today announced it has entered into a strategic collaboration with I-Mab to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions. Olamkicept is the first and only clinical stage...

 전체 기업